The Wee1 Inhibitor MK1775 In Combination With Cytarabine (AraC) Has Potent Activity In AML By Completely Abrogating DNA Damage and Cell Cycle Checkpoint Repair Capacity Via The Mrn/NBS1 Complex

第1周 支票1 DNA修复 雷达51 生物 细胞周期检查点 DNA损伤 细胞周期 癌症研究 综合征如奈梅亨破损综合症 同源重组 细胞周期蛋白依赖激酶1 遗传学 细胞 DNA 共济失调毛细血管扩张
作者
Leena Chaudhuri,James M Bogenberger,Lisa Z. Sproat,James L. Slack,Veena Fauble,Raoul Tibes
出处
期刊:Blood [Elsevier BV]
卷期号:122 (21): 3831-3831 被引量:1
标识
DOI:10.1182/blood.v122.21.3831.3831
摘要

Abstract Cytarabine (AraC) resistance is a fundamental feature of refractory/relapsed AML. RNA interference (RNAi) screens conducted in our laboratory recently identified WEE1 kinase (WEE1) as one of the top candidate genes and target in leukemias in combination with AraC. WEE1 is a tyrosine kinase belonging to the Ser/Thr family of protein kinases and acts as a negative regulator of mitotic entry by controlling DNA damage (DDR) and cell cycle checkpoint responses. The WEE1 inhibitor MK1775 potently synergizes with AraC ex vivo and in vitro and clinical trials are in preparation. However, the mechanism of action for the anti-leukemic activity of MK1775 with AraC remains unknown. To elucidate genes mediating activity of the combination, we first performed siRNA rescue screens silencing a custom set of 44 genes involved in WEE1 regulation under combined AraC + MK1775 to identify sensitizers and markers of resistance. The MRN (MRE11, Rad51, NBS1) complex and particularly NBS1 were potent modifiers of AraC and MK1775. Focusing on NBS1 since it is proposed to centrally regulate the defense capacity of leukemic cells, we identified that NBS1 phosphorylation at Ser343 (the ATM regulation site) is significantly altered both in cell lines and primary AML samples under combined AraC+MK1775 treatment as compared to single agent MK1775. In parallel, lower phosphorylation of ATMS1981(an autophosphorylation site in response to DNA strand breaks), was observed indicating that the ATM-CHEK1 pathway is not activated under co-treatment. Further Homologous recombination (HR)-mediated repair was compromised by AraC+MK1775 shown by DR-GFP expression vector to measure intracellular HR capacity: post-transfection of the I-SceI nuclease which cleaves non-functioning GFP tandem repeats to form a functional GFP unit, the HR was reduced with the combination. Consistently other HR markers decreased as well. Delayed accumulation of Cyclin A (indicative of S-phase progression) and greater inhibition of phospho-Cdk2Y15in synchronized cells treated with AraC + MK1775 in comparison to controls was observed. In addition the cell cycle was globally dysregulated by slower S-phase kinetics (progression), a completely abrogated G2/M checkpoint/phase as well as de-regulated DNA replication origin formation and firing as evidenced by Cdt1 and Mus81. As a consequence high single and double strand breaks (ɣH2AX) were observed with an increase in phospho-histone H3 in AraC + MK1775 treated cells compared to untreated cells or MK1775 single agent, confirming faster mitotic entry. Changes were followed by massive induction of apoptosis. Since WEE1 is implicated in leukemic stem cell maintenance we examined the long term effects of the combination in colony forming assays. AraC + MK1775 treated leukemic cells obtained from patients with AML were re-plated on Methocult after drug washout and colonies counted after 14 days. While MK1775 as a single agent could reduce colony formation by 4 fold compared to controls and lower dose AraC, co-treatment with low to moderate doses of AraC and MK1775 reduced colony formation by more than 7 fold and to almost zero in some primary specimens. Taken together, these results suggest that leukemia cells co-treated with AraC + MK1775 lost their ability to activate DNA damage and repair pathways mainly by compromising the MRN complex via NBS1 with subsequently reduced HR. The combination (as opposed to single agents) almost complete dysregulated the cell cycle and its checkpoints lead to DNA damage, genomic instability and rapid exit from the cell cycle with cell death via apoptosis. Thus we have molecularly characterized the detailed mechanisms underlying the potent AraC+WEE1 inhibition in AML and describe for the first time a therapeutic combination that has the potential to abrogate the MRN and NBS1 repair capacity which is central for drug resistance in AML. A key implication of our work is to provide a clinical rationale, mechanistic understanding and suggestions for biomarkers to clinically evaluate AraC + MK1775 in patients with AML. Disclosures: No relevant conflicts of interest to declare.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
文艺的语蝶完成签到,获得积分10
4秒前
wertherlzl完成签到 ,获得积分10
4秒前
4秒前
冰冰完成签到,获得积分10
4秒前
机智小天发布了新的文献求助10
7秒前
复杂夜梦的应助被zuo20050727采纳,获得10
8秒前
9秒前
9秒前
黎明的曙光完成签到,获得积分10
10秒前
诗酒梦芳华完成签到 ,获得积分10
11秒前
yi发布了新的文献求助10
14秒前
海的呼唤发布了新的文献求助10
14秒前
orange驳回了英姑的应助
15秒前
chenying完成签到 ,获得积分0
17秒前
18秒前
tang完成签到,获得积分10
18秒前
忧心的藏鸟完成签到 ,获得积分10
20秒前
XIXILI完成签到 ,获得积分10
20秒前
20秒前
开朗的向日葵完成签到 ,获得积分10
21秒前
材料人完成签到,获得积分10
23秒前
CCCCC发布了新的文献求助10
25秒前
无花果的应助被海的呼唤采纳,获得10
28秒前
徐梦曦完成签到 ,获得积分10
28秒前
Owen的应助被ferrumNjr采纳,获得10
29秒前
晨光完成签到,获得积分10
30秒前
内向忆南完成签到,获得积分10
31秒前
Lucky.完成签到 ,获得积分0
31秒前
khh完成签到 ,获得积分10
34秒前
风清完成签到 ,获得积分10
35秒前
香蕉觅云的应助被wsq采纳,获得10
39秒前
虚心的幻梅完成签到 ,获得积分10
40秒前
天真的棉花糖完成签到 ,获得积分10
40秒前
Dr_nie完成签到,获得积分10
40秒前
柠檬完成签到 ,获得积分10
40秒前
hilufite完成签到 ,获得积分10
40秒前
繁荣的安白完成签到 ,获得积分10
43秒前
43秒前
一叶知秋完成签到,获得积分10
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195363
求助须知:如何正确求助?哪些是违规求助? 9581006
关于积分的说明 21873433
捐赠科研通 7795465
什么是DOI,文献DOI怎么找? 3437988
关于科研通互助平台的介绍 2561364
邀请新用户注册赠送积分活动 2484748